Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 799 across all filing types
Latest filing 2021-03-11 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming Group to Present at BioCapital Europe 2021
Regulatory Filings Classification · 95% confidence The document is titled a "Press release" and announces that the CEO will present at the 'BioCapital Europe 2021' conference. It provides details about the presentation time and location, and includes boilerplate information about the company and forward-looking statements. Crucially, it is an announcement about an upcoming event (a presentation at an investment conference), not the release of a formal financial report (like 10-K, IR, or ER) or the transcript of a call. Since it is an announcement related to investor relations and corporate activity that doesn't fit the specific categories like DIV, CAP, or MANG, it falls best under the general regulatory/corporate announcement category, which is RNS (Regulatory Filings), as it is a formal communication to the market.
2021-03-11 English
6-K
Regulatory Filings
2021-03-04 English
Pharming Group reports financial results for full year 2020
Regulatory Filings
2021-03-04 English
Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program ‘navigateAPDS’ in US and Canada
Regulatory Filings Classification · 100% confidence The document is a press release announcing a collaboration between Pharming Group and Invitae Corporation to launch a genetic testing program ('navigateAPDS') for a rare disease. It contains a title, date, executive commentary, details about the program, and standard 'About Us' sections, concluding with forward-looking statements and contact information. This format is characteristic of an official company announcement intended for immediate public disclosure, often preceding or accompanying a formal regulatory filing. Since it is an announcement of a business development/partnership rather than a comprehensive financial report (10-K, IR), a specific financial result (ER), or a formal shareholder vote material (DEF 14A), it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is not short enough to definitively be an RPA based on the 'Menu vs Meal' rule, as it contains substantial operational and background information, suggesting it is the primary disclosure itself.
2021-03-02 English
6-K Filing
Regulatory Filings
2021-03-02 English
424B4
Regulatory Filings
2020-12-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.